Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Patients who stay on starter doses of semaglutide or tirzepatide still lose some weight, but far less than those who escalate to higher doses. A new study of over 1,000 real-world patients found modest weight loss and fewer side effects at low doses — but the two drugs aren't interchangeable, with tirzepatide linked to more adverse events including kidney injury.
Many patients on GLP-1 drugs like Ozempic and Zepbound never make it to the recommended maintenance dose — whether due to cost, side effects, or personal goals. A new real-world study published in Biology Methods & Protocols offers some reassurance: staying on the lowest starter doses still delivers measurable weight loss, just not the dramatic results seen in clinical trials.
Researchers analyzed data from 534 patients each on low-dose semaglutide (0.25 mg) and tirzepatide (2.5 mg) for at least six months. Both groups lost weight, but the results were modest compared to higher-dose benchmarks. Importantly, the two drugs showed meaningful differences in their side effect profiles — tirzepatide was linked to higher rates of kidney injury, constipation, and muscle cramps, while semaglutide showed more ear inflammation and ankle swelling.
By the Numbers:
Why it matters: Millions of patients are taking GLP-1 drugs at sub-therapeutic doses, yet clinical guidance has largely been built around higher-dose trial data. This study highlights that low-dose users deserve tailored counseling on realistic outcomes and drug-specific risks.
